Proteomics

Dataset Information

0

Prkar1a_SILAC_Proteomics


ABSTRACT: Evading immune destruction is a hallmark of cancer and a key feature for the resistance to cancer immunotherapy. Genetic alterations can directly influence the nature of cancer cells in the native tumor microenvironment to mediate immune escape. Our genome-scale in vivo CRISPR screens robustly identified multiple regulators of tumor-intrinsic factors that alter the ability of cells to grow as tumors across different levels of immunocompetence. As a convergent hit from these screens, Prkar1a mutant cells are able to robustly outgrow as tumors in fully immunocompetent hosts. Functional interrogation showed that Prkar1a loss greatly altered the transcriptome and proteome involved in inflammatory and immune responses as well as extracellular protein production. Single cell transcriptomic profiling and flow cytometry analysis mapped the tumor microenvironment of Prkar1a mutant tumors, and revealed the transcriptomic alterations in host myeloid cells. Taken together, tumor-intrinsic mutations in Prkar1a led to drastic alterations in the genetic program of cancer cells, thereby remodeling the tumor microenvironment.

INSTRUMENT(S): LTQ Orbitrap

ORGANISM(S): Mus Musculus (mouse)

TISSUE(S): Hepatocyte

SUBMITTER: Paul Renauer  

LAB HEAD: Sidi Chen

PROVIDER: PXD011837 | Pride | 2020-05-26

REPOSITORIES: Pride

altmetric image

Publications


The genetic makeup of cancer cells directs oncogenesis and influences the tumor microenvironment. In this study, we massively profiled genes that functionally drive tumorigenesis using genome-scale in vivo CRISPR screens in hosts with different levels of immunocompetence. As a convergent hit from these screens, Prkar1a mutant cells are able to robustly outgrow as tumors in fully immunocompetent hosts. Functional interrogation showed that Prkar1a loss greatly altered the transcriptome and proteom  ...[more]

Similar Datasets

2019-12-13 | GSE123824 | GEO
2023-01-31 | GSE200628 | GEO
2019-03-18 | MSV000083594 | MassIVE
2023-02-21 | PXD039472 | Pride
2024-01-15 | PXD041186 | Pride
2016-12-01 | MSV000080374 | MassIVE
2021-10-21 | GSE121570 | GEO
2017-09-12 | GSE103713 | GEO
2017-09-12 | GSE103712 | GEO
2017-09-12 | GSE103711 | GEO